MRX 951
Alternative Names: MRX-951Latest Information Update: 11 Jun 2003
At a glance
- Originator ImaRx Therapeutics
- Class
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Jun 2003 MRX 951 is available for licensing (http://www.imarx.com)
- 11 Jun 2003 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 08 Jan 2001 New profile